查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1859994

無血清冷凍培養基：全球市佔率及排名、總收入及需求預測（2025-2031年）

Serum-Free Freezing Media - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 124 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球無血清冷凍培養基市場規模估計為 2.43 億美元，預計到 2031 年將達到 4.06 億美元，在預測期（2025-2031 年）內複合年成長率為 8.1%。

本報告對近期與無血清冷凍培養基相關的關稅調整和國際戰略反制措施進行了全面評估，包括其對跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組的影響。

無血清凍存液是一種專門用於細胞和組織長期冷凍保存的凍存液，無需使用動物性血清（例如牛）。這類凍存液主要成分為化學成分明確的成分、重組或植物來源替代品、合成冷凍保護劑（例如DMSO或其他冷凍保護劑）、緩衝系統、滲透壓調節劑和必需營養素。其目的是在超低溫（通常為-80°C至液態氮）下，於儲存、運輸以及後續的解凍、培養/應用過程中，維持細胞的活力、形態和功能完整性。與含血清凍存液相比，無血清凍存液具有更高的批次間一致性、更低的動物性污染和病原體傳播風險、更符合倫理和監管標準，並且在科研和工業生物生產環境中均具有更高的可重複性。 2024 年，全球無血清凍存液產量達到約 166,000 公升，全球平均市場價格約為每公升 1,460 美元。

隨著生物製藥研究、細胞和基因治療以及再生醫學在全球的快速發展，無血清凍存培養基正處於市場快速擴張階段。首先，許多國家的管理體制正在收緊對動物性材料相關風險（病原體、交叉污染和倫理問題）的要求，迫使產業轉型為無血清系統。其次，由於學術機構和工業用戶都優先考慮可重複性和批間一致性，因此無血清系統可以減少血清相關的變異性，並提高解凍後細胞的活力、形態和功能完整性。第三，全球正在開發平臺的細胞療法和疫苗數量以及投資金額都在不斷成長，這要求凍存培養基必須具備卓越的安全性、穩定性和儲存/運輸能力。第四，新興市場（特別是中國、印度和其他亞太國家）正在迅速加強其生物技術基礎設施、研發投資和政策支持，這為無血清凍存培養基的本地化生產和市場滲透創造了巨大的機會。同時，產業內的技術創新也在加速發展。一些公司在其年度報告中表示，他們已實現了關鍵原料和冷凍保護劑的內部開發，並建立了涵蓋從基礎研究到商業生產的一體化平台，從而降低了成本並提高了應對力（來源：公司年度報告）。

儘管存在這些重大機遇，但也存在著許多挑戰。首先，無血清凍存液的配方往往更為複雜，需要更高品質、更高純度的原料以及嚴格的生產流程（例如，無菌、低溫運輸和凍融損傷控制），所有這些都會增加生產成本並降低利潤率，尤其對於中小製造商而言。其次，細胞型特異性。各種細胞株（例如，幹細胞、基因編輯細胞株和高密度生產細胞株）各有其獨特的要求。通用的無血清凍存液可能無法為所有細胞類型提供最佳的活力和功能，因此需要耗費大量的研發週期和性能檢驗。第三，監理和合規風險。例如，安全認證、無殘留動物成分認證、驗證、批次間一致性和生物相容性都需要時間和資源。第四，競爭風險：像賽默飛世爾科技和默克這樣的全球知名企業擁有強大的品牌影響力、規模和分銷網路。對於新參與企業或本地企業而言，建立品牌信譽和品質口碑可能既昂貴又耗時。此外，還存在知識產權被侵犯或洩露的風險，以及由於下游客戶需求變化導致配方過時的風險。

下游需求正從基礎研究轉向多元化和專業化。學術機構仍然是重要的需求來源，他們優先選擇能夠維持冷凍後細胞活力、形態和基因表現表現穩定的凍存液，以支持細胞生物學、發育生物學、免疫學和幹細胞研究。製藥和生物技術公司需要符合GMP或同等監管標準的凍存液，以貫穿臨床前、臨床和商業化階段，並在儲存和運輸過程中保持良好的表現。 CDMO/CRO服務供應商正成為重要的中間用戶，他們需要具有廣泛適用性、品質穩定和卓越客戶支援的產品，以服務其眾多客戶。此外，再生醫學、組織工程、細胞農業和肉類替代品等新興下游領域提出了日益嚴格的要求。這些要求包括高回收率、低毒性、不含動物性成分、批次間一致性高、成本效益。在成熟市場（北美和歐洲），下游需求強調合規性和高效能。與此同時，亞太地區（尤其是中國）正經歷快速成長，但價格敏感度和本地供應是關鍵因素。中國企業（例如，億橋神州）報告稱，其無血清培養基已與多種細胞類型相容，包括HEK-293細胞和昆蟲細胞，這表明市場對多種細胞類型的需求正在成長。

無血清凍存培養基的成分包括冷凍保護劑（例如二甲基亞碸、甘油、丙二醇或新型低毒替代品）、營養成分（胺基酸、維生素、無機鹽、緩衝鹽）、滲透壓調節劑（用於控制凍融過程中的滲透壓壓力）、重組蛋白或生長因子或植物來源/合成替代品、無菌水、穩定劑和適當的緩衝液。其中，DMSO 或等效的保護劑仍然是主流選擇，因為許多培養基仍然含有 DMSO。雖然人們對非 DMSO 替代品的興趣日益成長，但它們在性能或市場佔有率方面尚未完全取代 DMSO。高純度氨基酸、生長因子或重組蛋白價格昂貴，且供應商通常供應有限，這使得上游供應商具有優勢。品質、認證（例如 GMP 或同等認證）和供應穩定性是關鍵的風險因素。純度和均一性至關重要。批次/批次間的雜質和污染（化學或微生物污染）會顯著降低解凍後的活性，並改變其功能特性。此外，隨著全球需求的成長（尤其是在快速成長的市場），成本和前置作業時間會受到多種因素的影響，例如經認證的高純度原料的供應情況、物流（低溫運輸和運輸）、進出口政策以及關稅。一些公司，特別是中國的公司，在其年度報告中表示，他們正在開發或自主生產關鍵原料和組件，以減少對海外供應商的依賴，控制成本並降低供應鏈風險。

本報告旨在按地區/國家、類型和應用對全球無血清冷凍培養基市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

本報告以2024年為基準年，對無血清凍存液市場規模、估算和預測進行了闡述，單位為銷售量（千升）和收入（百萬美元），涵蓋2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並就無血清凍存液市場做出明智的商業決策。

市場區隔

公司

  • Thermo Fisher
  • Merck
  • Zenoaq
  • STEMCELL
  • Cytiva
  • BioLifeSolutions
  • Fujifilm
  • Lonza
  • Sartorius
  • Nippon Genetics
  • HiMedia
  • PromoCell

按類型分類的細分市場

  • 含有二甲基亞碸
  • 不含DMSO

應用領域

  • 學術和研究機構
  • 製藥和生物技術公司

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Serum-Free Freezing Media was estimated to be worth US$ 243 million in 2024 and is forecast to a readjusted size of US$ 406 million by 2031 with a CAGR of 8.1% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Serum-Free Freezing Media cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Serum-Free Freezing Media refers to specialized cryopreservation media designed for long-term freezing storage of cells or tissues without using animal-derived sera (such as fetal bovine serum). Instead, these media rely on chemically defined components, recombinant or plant-derived substitutes, or synthetic cryoprotectants (e.g., DMSO or alternative cryoprotectants), buffering systems, osmotic regulators, and essential nutrients. Its purpose is to maintain cell viability, morphology, and functional integrity under ultra-low temperatures (often -80 °C down to liquid nitrogen) for storage, transport, or downstream thawing and culture/applications. Compared to serum-containing systems, serum-free freezing media offer higher batch-to-batch consistency, lower risk of animal component contamination or pathogen transmission, better alignment with ethical/regulatory standards, and improved reproducibility in both research and industrial bioproduction settings.In 2024, global Serum-Free Freezing Media production reached approximately 166 k L, with an average global market price of around US$ 1460 per L.

Against the backdrop of rapid advances in biopharmaceutical research, cell & gene therapies, and regenerative medicine globally, serum-free freezing media is at a phase of strong market expansion. First, regulatory regimes in many countries are strengthening requirements around risks associated with animal-derived materials (pathogens, cross-contamination, ethical concerns), pushing the industry to shift from serum-containing to serum-free systems. Second, both academic and industrial users are emphasizing reproducibility and batch-to-batch consistency; serum-free systems offer reduced variability introduced by serum, improving post-thaw cell viability, morphology, and functional integrity. Third, the number and investment volume of cell-based therapy/vaccine pipelines are rising worldwide; these applications demand freezing media with high safety, stability, and storage/transport performance. Fourth, emerging markets-especially in China, India, and other Asia-Pacific countries-are rapidly enhancing biotech infrastructure, R&D investment, and policy support, creating large opportunity for local manufacture and market penetration of serum-free freezing media. Meanwhile, technological innovation inside the industry is accelerating: some companies report in their annual reports that they have achieved in-house development of key raw materials or cryoprotectants and built integrated platforms spanning from basic research to commercial production, which helps lower costs and improve responsiveness. (Sources: enterprise annual reports).

Despite the strong opportunities, there are significant challenges. First, serum-free freezing media tend to have higher formulation complexity and require higher quality/purity of raw materials and stricter manufacturing processes (sterility, cold chain, control of freeze-thaw damage etc.), which all increase production cost and reduce margin, particularly for smaller manufacturers. Second, cell-type specificity: various cell lines (stem cells, gene-edited lines, high density production cell lines) each have unique requirements; a generic serum-free freezing medium may not give optimum viability/function across all, meaning long R&D cycles and performance validation are needed. Third, regulatory and compliance risks: for example, proving safety, proving residual animal-component absence, performing validation, batch consistency, biocompatibility, all take time and resources. Fourth, competitive risk: established global players like Thermo Fisher, Merck etc. have strong brand, scale, distribution; for new entrants or local firms, building brand trust, quality reputation is expensive and time consuming. There is also risk of IP infringement or leakage, or formula becoming obsolete if downstream customer needs change.

Downstream demand is trending from basic research toward greater diversity and specialization. Academic institutions remain important demand centers, prioritizing freezing media that deliver stable post-thaw viability, morphology, gene expression etc., to support cell biology, developmental biology, immunology, stem cell research. Pharma / biotech companies require freezing media that meet GMP or comparable regulatory standards across preclinical, clinical, commercial phases, and that perform well during storage/transport. CDMO / CRO service providers are becoming key mid-users, supporting many clients and needing broadly applicable, consistent quality products along with good customer support. Also, emerging downstream sectors-regenerative medicine, tissue engineering, cellular agriculture, alternative meats, etc.-are starting to specify more stringent requirements: high recovery rate, low toxicity, no animal-origin components, high batch consistency, and cost-effectiveness. Geographically, downstream demand in mature markets (North America, Europe) emphasizes compliance, premium performance; in Asia-Pacific (especially China), the growth is rapid, but price sensitivity and local supply are important factors. Chinese firms (e.g. Yiqiao Shenzhou) report that their serum-free media already cover cell types like HEK-293, insect cells etc., showing cell-type diversification of demand.

The upstream raw materials for serum-free freezing media include: cryoprotectants (e.g. DMSO, glycerol, propylene glycol or newer lower toxicity alternatives), nutritional components (amino acids, vitamins, inorganic salts, buffering salts), osmotic regulators (to manage osmotic stress during freeze/thaw), recombinant proteins or growth factors or plant/synthetic substitutes, sterile water, stabilizers and appropriate buffering agents. Among these, DMSO or equivalent protectants remain dominant because many media still include DMSO; though non-DMSO alternatives are gaining interest, they have not yet fully displaced DMSO in performance or market share. High purity amino acids, growth factors or recombinant proteins are expensive and often supplied by few vendors, giving upstream suppliers leverage and making quality, certification (e.g. GMP or equivalent), and supply stability key risks. Purity and consistency are absolutely crucial: any batch/lot impurity or contamination (chemical, microbial) can dramatically reduce post-thaw viability or alter functional behavior. Also, as demand rises globally (especially in fast-growing markets), availability of certified high-purity material, logistics (cold chain, transport), import/export policies, tariffs etc. affect cost and lead time. Some companies (notably in China) in their annual reports explicitly state that they are developing or internally producing key raw materials / componentsto reduce dependence on foreign suppliers, control cost and reduce supply chain risk.

This report aims to provide a comprehensive presentation of the global market for Serum-Free Freezing Media, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Serum-Free Freezing Media by region & country, by Type, and by Application.

The Serum-Free Freezing Media market size, estimations, and forecasts are provided in terms of sales volume (K Liters) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Serum-Free Freezing Media.

Market Segmentation

By Company

  • Thermo Fisher
  • Merck
  • Zenoaq
  • STEMCELL
  • Cytiva
  • BioLifeSolutions
  • Fujifilm
  • Lonza
  • Sartorius
  • Nippon Genetics
  • HiMedia
  • PromoCell

Segment by Type

  • With DMSO
  • DMSO-free

Segment by Application

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Serum-Free Freezing Media manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Serum-Free Freezing Media in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Serum-Free Freezing Media in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Serum-Free Freezing Media Product Introduction
  • 1.2 Global Serum-Free Freezing Media Market Size Forecast
    • 1.2.1 Global Serum-Free Freezing Media Sales Value (2020-2031)
    • 1.2.2 Global Serum-Free Freezing Media Sales Volume (2020-2031)
    • 1.2.3 Global Serum-Free Freezing Media Sales Price (2020-2031)
  • 1.3 Serum-Free Freezing Media Market Trends & Drivers
    • 1.3.1 Serum-Free Freezing Media Industry Trends
    • 1.3.2 Serum-Free Freezing Media Market Drivers & Opportunity
    • 1.3.3 Serum-Free Freezing Media Market Challenges
    • 1.3.4 Serum-Free Freezing Media Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Serum-Free Freezing Media Players Revenue Ranking (2024)
  • 2.2 Global Serum-Free Freezing Media Revenue by Company (2020-2025)
  • 2.3 Global Serum-Free Freezing Media Players Sales Volume Ranking (2024)
  • 2.4 Global Serum-Free Freezing Media Sales Volume by Company Players (2020-2025)
  • 2.5 Global Serum-Free Freezing Media Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Serum-Free Freezing Media Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Serum-Free Freezing Media Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Serum-Free Freezing Media
  • 2.9 Serum-Free Freezing Media Market Competitive Analysis
    • 2.9.1 Serum-Free Freezing Media Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Serum-Free Freezing Media Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Serum-Free Freezing Media as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 With DMSO
    • 3.1.2 DMSO-free
  • 3.2 Global Serum-Free Freezing Media Sales Value by Type
    • 3.2.1 Global Serum-Free Freezing Media Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Serum-Free Freezing Media Sales Value, by Type (2020-2031)
    • 3.2.3 Global Serum-Free Freezing Media Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Serum-Free Freezing Media Sales Volume by Type
    • 3.3.1 Global Serum-Free Freezing Media Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Serum-Free Freezing Media Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Serum-Free Freezing Media Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Serum-Free Freezing Media Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Academic & Research Institutes
    • 4.1.2 Pharmaceutical & Biotechnology Companies
  • 4.2 Global Serum-Free Freezing Media Sales Value by Application
    • 4.2.1 Global Serum-Free Freezing Media Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Serum-Free Freezing Media Sales Value, by Application (2020-2031)
    • 4.2.3 Global Serum-Free Freezing Media Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Serum-Free Freezing Media Sales Volume by Application
    • 4.3.1 Global Serum-Free Freezing Media Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Serum-Free Freezing Media Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Serum-Free Freezing Media Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Serum-Free Freezing Media Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Serum-Free Freezing Media Sales Value by Region
    • 5.1.1 Global Serum-Free Freezing Media Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Serum-Free Freezing Media Sales Value by Region (2020-2025)
    • 5.1.3 Global Serum-Free Freezing Media Sales Value by Region (2026-2031)
    • 5.1.4 Global Serum-Free Freezing Media Sales Value by Region (%), (2020-2031)
  • 5.2 Global Serum-Free Freezing Media Sales Volume by Region
    • 5.2.1 Global Serum-Free Freezing Media Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Serum-Free Freezing Media Sales Volume by Region (2020-2025)
    • 5.2.3 Global Serum-Free Freezing Media Sales Volume by Region (2026-2031)
    • 5.2.4 Global Serum-Free Freezing Media Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Serum-Free Freezing Media Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.4.2 North America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.5.2 Europe Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Serum-Free Freezing Media Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.7.2 South America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Serum-Free Freezing Media Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Serum-Free Freezing Media Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Serum-Free Freezing Media Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.3.2 United States Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.4.2 Europe Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.5.2 China Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.6.2 Japan Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.7.2 South Korea Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.9.2 India Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Thermo Fisher
    • 7.1.1 Thermo Fisher Company Information
    • 7.1.2 Thermo Fisher Introduction and Business Overview
    • 7.1.3 Thermo Fisher Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Thermo Fisher Serum-Free Freezing Media Product Offerings
    • 7.1.5 Thermo Fisher Recent Development
  • 7.2 Merck
    • 7.2.1 Merck Company Information
    • 7.2.2 Merck Introduction and Business Overview
    • 7.2.3 Merck Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Merck Serum-Free Freezing Media Product Offerings
    • 7.2.5 Merck Recent Development
  • 7.3 Zenoaq
    • 7.3.1 Zenoaq Company Information
    • 7.3.2 Zenoaq Introduction and Business Overview
    • 7.3.3 Zenoaq Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Zenoaq Serum-Free Freezing Media Product Offerings
    • 7.3.5 Zenoaq Recent Development
  • 7.4 STEMCELL
    • 7.4.1 STEMCELL Company Information
    • 7.4.2 STEMCELL Introduction and Business Overview
    • 7.4.3 STEMCELL Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 STEMCELL Serum-Free Freezing Media Product Offerings
    • 7.4.5 STEMCELL Recent Development
  • 7.5 Cytiva
    • 7.5.1 Cytiva Company Information
    • 7.5.2 Cytiva Introduction and Business Overview
    • 7.5.3 Cytiva Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Cytiva Serum-Free Freezing Media Product Offerings
    • 7.5.5 Cytiva Recent Development
  • 7.6 BioLifeSolutions
    • 7.6.1 BioLifeSolutions Company Information
    • 7.6.2 BioLifeSolutions Introduction and Business Overview
    • 7.6.3 BioLifeSolutions Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 BioLifeSolutions Serum-Free Freezing Media Product Offerings
    • 7.6.5 BioLifeSolutions Recent Development
  • 7.7 Fujifilm
    • 7.7.1 Fujifilm Company Information
    • 7.7.2 Fujifilm Introduction and Business Overview
    • 7.7.3 Fujifilm Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Fujifilm Serum-Free Freezing Media Product Offerings
    • 7.7.5 Fujifilm Recent Development
  • 7.8 Lonza
    • 7.8.1 Lonza Company Information
    • 7.8.2 Lonza Introduction and Business Overview
    • 7.8.3 Lonza Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Lonza Serum-Free Freezing Media Product Offerings
    • 7.8.5 Lonza Recent Development
  • 7.9 Sartorius
    • 7.9.1 Sartorius Company Information
    • 7.9.2 Sartorius Introduction and Business Overview
    • 7.9.3 Sartorius Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Sartorius Serum-Free Freezing Media Product Offerings
    • 7.9.5 Sartorius Recent Development
  • 7.10 Nippon Genetics
    • 7.10.1 Nippon Genetics Company Information
    • 7.10.2 Nippon Genetics Introduction and Business Overview
    • 7.10.3 Nippon Genetics Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Nippon Genetics Serum-Free Freezing Media Product Offerings
    • 7.10.5 Nippon Genetics Recent Development
  • 7.11 HiMedia
    • 7.11.1 HiMedia Company Information
    • 7.11.2 HiMedia Introduction and Business Overview
    • 7.11.3 HiMedia Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 HiMedia Serum-Free Freezing Media Product Offerings
    • 7.11.5 HiMedia Recent Development
  • 7.12 PromoCell
    • 7.12.1 PromoCell Company Information
    • 7.12.2 PromoCell Introduction and Business Overview
    • 7.12.3 PromoCell Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 PromoCell Serum-Free Freezing Media Product Offerings
    • 7.12.5 PromoCell Recent Development

8 Industry Chain Analysis

  • 8.1 Serum-Free Freezing Media Industrial Chain
  • 8.2 Serum-Free Freezing Media Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Serum-Free Freezing Media Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Serum-Free Freezing Media Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Serum-Free Freezing Media Market Trends
  • Table 2. Serum-Free Freezing Media Market Drivers & Opportunity
  • Table 3. Serum-Free Freezing Media Market Challenges
  • Table 4. Serum-Free Freezing Media Market Restraints
  • Table 5. Global Serum-Free Freezing Media Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Serum-Free Freezing Media Revenue Market Share by Company (2020-2025)
  • Table 7. Global Serum-Free Freezing Media Sales Volume by Company (2020-2025) & (K Liters)
  • Table 8. Global Serum-Free Freezing Media Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Serum-Free Freezing Media Price by Company (2020-2025) & (USD/Liter)
  • Table 10. Key Manufacturers Serum-Free Freezing Media Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Serum-Free Freezing Media Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Serum-Free Freezing Media
  • Table 13. Global Serum-Free Freezing Media Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Serum-Free Freezing Media as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Serum-Free Freezing Media Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Serum-Free Freezing Media Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Serum-Free Freezing Media Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Serum-Free Freezing Media Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Serum-Free Freezing Media Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Serum-Free Freezing Media Sales Volume by Type: 2020 VS 2024 VS 2031 (K Liters)
  • Table 22. Global Serum-Free Freezing Media Sales Volume by Type (2020-2025) & (K Liters)
  • Table 23. Global Serum-Free Freezing Media Sales Volume by Type (2026-2031) & (K Liters)
  • Table 24. Global Serum-Free Freezing Media Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Serum-Free Freezing Media Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Serum-Free Freezing Media Price by Type (2020-2025) & (USD/Liter)
  • Table 27. Global Serum-Free Freezing Media Price by Type (2026-2031) & (USD/Liter)
  • Table 28. Global Serum-Free Freezing Media Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Serum-Free Freezing Media Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Serum-Free Freezing Media Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Serum-Free Freezing Media Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Serum-Free Freezing Media Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Serum-Free Freezing Media Sales Volume by Application: 2020 VS 2024 VS 2031 (K Liters)
  • Table 34. Global Serum-Free Freezing Media Sales Volume by Application (2020-2025) & (K Liters)
  • Table 35. Global Serum-Free Freezing Media Sales Volume by Application (2026-2031) & (K Liters)
  • Table 36. Global Serum-Free Freezing Media Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Serum-Free Freezing Media Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Serum-Free Freezing Media Price by Application (2020-2025) & (USD/Liter)
  • Table 39. Global Serum-Free Freezing Media Price by Application (2026-2031) & (USD/Liter)
  • Table 40. Global Serum-Free Freezing Media Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Serum-Free Freezing Media Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Serum-Free Freezing Media Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Serum-Free Freezing Media Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Serum-Free Freezing Media Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Serum-Free Freezing Media Sales Volume by Region (K Liters): 2020 VS 2024 VS 2031
  • Table 46. Global Serum-Free Freezing Media Sales Volume by Region (2020-2025) & (K Liters)
  • Table 47. Global Serum-Free Freezing Media Sales Volume by Region (2026-2031) & (K Liters)
  • Table 48. Global Serum-Free Freezing Media Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Serum-Free Freezing Media Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Serum-Free Freezing Media Average Price by Region (2020-2025) & (USD/Liter)
  • Table 51. Global Serum-Free Freezing Media Average Price by Region (2026-2031) & (USD/Liter)
  • Table 52. Key Countries/Regions Serum-Free Freezing Media Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Serum-Free Freezing Media Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Serum-Free Freezing Media Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Serum-Free Freezing Media Sales Volume, (2020-2025) & (K Liters)
  • Table 56. Key Countries/Regions Serum-Free Freezing Media Sales Volume, (2026-2031) & (K Liters)
  • Table 57. Thermo Fisher Company Information
  • Table 58. Thermo Fisher Introduction and Business Overview
  • Table 59. Thermo Fisher Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 60. Thermo Fisher Serum-Free Freezing Media Product Offerings
  • Table 61. Thermo Fisher Recent Development
  • Table 62. Merck Company Information
  • Table 63. Merck Introduction and Business Overview
  • Table 64. Merck Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 65. Merck Serum-Free Freezing Media Product Offerings
  • Table 66. Merck Recent Development
  • Table 67. Zenoaq Company Information
  • Table 68. Zenoaq Introduction and Business Overview
  • Table 69. Zenoaq Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 70. Zenoaq Serum-Free Freezing Media Product Offerings
  • Table 71. Zenoaq Recent Development
  • Table 72. STEMCELL Company Information
  • Table 73. STEMCELL Introduction and Business Overview
  • Table 74. STEMCELL Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 75. STEMCELL Serum-Free Freezing Media Product Offerings
  • Table 76. STEMCELL Recent Development
  • Table 77. Cytiva Company Information
  • Table 78. Cytiva Introduction and Business Overview
  • Table 79. Cytiva Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 80. Cytiva Serum-Free Freezing Media Product Offerings
  • Table 81. Cytiva Recent Development
  • Table 82. BioLifeSolutions Company Information
  • Table 83. BioLifeSolutions Introduction and Business Overview
  • Table 84. BioLifeSolutions Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 85. BioLifeSolutions Serum-Free Freezing Media Product Offerings
  • Table 86. BioLifeSolutions Recent Development
  • Table 87. Fujifilm Company Information
  • Table 88. Fujifilm Introduction and Business Overview
  • Table 89. Fujifilm Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 90. Fujifilm Serum-Free Freezing Media Product Offerings
  • Table 91. Fujifilm Recent Development
  • Table 92. Lonza Company Information
  • Table 93. Lonza Introduction and Business Overview
  • Table 94. Lonza Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 95. Lonza Serum-Free Freezing Media Product Offerings
  • Table 96. Lonza Recent Development
  • Table 97. Sartorius Company Information
  • Table 98. Sartorius Introduction and Business Overview
  • Table 99. Sartorius Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 100. Sartorius Serum-Free Freezing Media Product Offerings
  • Table 101. Sartorius Recent Development
  • Table 102. Nippon Genetics Company Information
  • Table 103. Nippon Genetics Introduction and Business Overview
  • Table 104. Nippon Genetics Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 105. Nippon Genetics Serum-Free Freezing Media Product Offerings
  • Table 106. Nippon Genetics Recent Development
  • Table 107. HiMedia Company Information
  • Table 108. HiMedia Introduction and Business Overview
  • Table 109. HiMedia Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 110. HiMedia Serum-Free Freezing Media Product Offerings
  • Table 111. HiMedia Recent Development
  • Table 112. PromoCell Company Information
  • Table 113. PromoCell Introduction and Business Overview
  • Table 114. PromoCell Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 115. PromoCell Serum-Free Freezing Media Product Offerings
  • Table 116. PromoCell Recent Development
  • Table 117. Key Raw Materials Lists
  • Table 118. Raw Materials Key Suppliers Lists
  • Table 119. Serum-Free Freezing Media Downstream Customers
  • Table 120. Serum-Free Freezing Media Distributors List
  • Table 121. Research Programs/Design for This Report
  • Table 122. Key Data Information from Secondary Sources
  • Table 123. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Serum-Free Freezing Media Product Picture
  • Figure 2. Global Serum-Free Freezing Media Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Serum-Free Freezing Media Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Serum-Free Freezing Media Sales Volume (2020-2031) & (K Liters)
  • Figure 5. Global Serum-Free Freezing Media Sales Price (2020-2031) & (USD/Liter)
  • Figure 6. Serum-Free Freezing Media Report Years Considered
  • Figure 7. Global Serum-Free Freezing Media Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Serum-Free Freezing Media Players Sales Volume Ranking (2024) & (K Liters)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Serum-Free Freezing Media Revenue in 2024
  • Figure 10. Serum-Free Freezing Media Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. With DMSO Picture
  • Figure 12. DMSO-free Picture
  • Figure 13. Global Serum-Free Freezing Media Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Serum-Free Freezing Media Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Serum-Free Freezing Media Sales Volume by Type (2020 VS 2024 VS 2031) & (K Liters)
  • Figure 16. Global Serum-Free Freezing Media Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Serum-Free Freezing Media Price by Type (2020-2031) & (USD/Liter)
  • Figure 18. Product Picture of Academic & Research Institutes
  • Figure 19. Product Picture of Pharmaceutical & Biotechnology Companies
  • Figure 20. Global Serum-Free Freezing Media Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 21. Global Serum-Free Freezing Media Sales Value Market Share by Application, 2024 & 2031
  • Figure 22. Global Serum-Free Freezing Media Sales Volume by Application (2020 VS 2024 VS 2031) & (K Liters)
  • Figure 23. Global Serum-Free Freezing Media Sales Volume Market Share by Application, 2024 & 2031
  • Figure 24. Global Serum-Free Freezing Media Price by Application (2020-2031) & (USD/Liter)
  • Figure 25. North America Serum-Free Freezing Media Sales Value (2020-2031) & (US$ Million)
  • Figure 26. North America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Europe Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Europe Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Asia Pacific Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Asia Pacific Serum-Free Freezing Media Sales Value by Region (%), 2024 VS 2031
  • Figure 31. South America Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. South America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • Figure 33. Middle East & Africa Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Middle East & Africa Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Key Countries/Regions Serum-Free Freezing Media Sales Value (%), (2020-2031)
  • Figure 36. Key Countries/Regions Serum-Free Freezing Media Sales Volume (%), (2020-2031)
  • Figure 37. United States Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. United States Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 39. United States Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Europe Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Europe Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Europe Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 43. China Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. China Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 45. China Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Japan Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Japan Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Japan Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 49. South Korea Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. South Korea Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 51. South Korea Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Southeast Asia Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 53. Southeast Asia Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 54. Southeast Asia Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 55. India Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 56. India Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 57. India Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 58. Serum-Free Freezing Media Industrial Chain
  • Figure 59. Serum-Free Freezing Media Manufacturing Cost Structure
  • Figure 60. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 61. Bottom-up and Top-down Approaches for This Report
  • Figure 62. Data Triangulation
  • Figure 63. Key Executives Interviewed